Microbix Clot-Buster Drug Fully-Funded for Return to U.S. Market

Microbix Biosystems Inc., a life sciences innovator, manufacturer and exporter, recently announced the reconfirmation of its agreement with Sequel Pharma, LLC to return Kinlytic® urokinase to market in the United States, followed by other geographies and clinical indications. Kinlytic is an enzyme derived from human cell cultures that dissolves the material of a blood clot. A further payment of US$ 2.0 million has been received by Microbix relating to this reconfirmation.

Microbix is an OBIO® member and an alumnus of the BDSP™ and H2BB™ programs.

Previous
Previous

OBIO® launches national health science technology training program powered by Upskill Canada

Next
Next

AmacaThera Closes Series A Extension to Advance Clinical Development of Long Acting, Localized, Non-Opioid Therapeutics to Improve Post-Surgery Patient Care